Saturday 17 October 2026
Export DRTS’s income statement to Excel — free account
Alpha Tau Medical Ltd.
DRTS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 100.0%, free cash flow fell 30.4% and total debt rose 12.8%, each against the same quarter a year earlier.
12.29
0.87
−6.61%
Follow DRTS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
0.00% | 0.00% | (70.85%) | 0.00% | |
| 0.00% | 0.00% | (46.94%) | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | (49.40%) | 0.00% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
— | — | 0.00 | 0.00 | |
Free Cash Flow |
— | — | — | (39.09) | |
Capital Expenditures |
— | — | — | (4.35) | |
| Other line items | |||||
Cash ROIC |
0.00% | 0.00% | 0.00% | (25.80%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | 0.00 | — | |
Research and Development Expense of Revenue |
— | — | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
— | — | 0.00% | — | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Interest Coverage |
— | — | (4.96) | — | |
Operating CF/Net income |
— | — | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.12 | |
Capex/Depreciation |
— | — | — | (1.90) | |
Revenue per Share |
— | — | 0.00 | — | |
Operating CF per Share |
— | — | 0.00 | 0.00 | |
Capex per Share |
— | — | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates